yusuf transient & persistent hypoglycemia in neonates
DESCRIPTION
The common problem of hypoglycemia in neonates. Its causes, diagnosis and treatment/management.TRANSCRIPT
![Page 1: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/1.jpg)
Neonatal Hypoglycemia : Transient & Persistent
MODERATORS-
PROF. S.M ALI
DR. UZMA FIRDAUS
DR. KASHIF ALI
PRESENTED BY- DR. YUSUF IMRAN
Date 19/12/2013
![Page 2: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/2.jpg)
GLUCOSE PHYSIOLOGY IN FETUS
Fetus obtains 60-70 % of its energy from Glucose.
All Fetal Glucose is derives from maternal circulation by facilitated diffusion.
The fetus stores glucose in the form of glycogen (liver, heart, lung, and skeletal muscle).
Most of the glycogen is made and stored in the last month of the 3rd trimester.
![Page 3: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/3.jpg)
ADAPTATION AT DELIVERY
When the umbilical cord is cut, source of Glucose is abruptly interrupted.
Glucose requirements exceed those of adults mainly b/c of increased ratio of brain to body mass.
To maintain Glucose levels newborn must respond by-
Glycogenolysis of hepatic stores.
Inducing Gluconeogenesis.
Utilizing exogenous nutrients from intermittent feeding.
![Page 4: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/4.jpg)
ADAPTATION CONT…
Maintenance of physiological plasma glucose concentration depends on a normal endocrine system.
Enzymes of glycogenolysis, gluconeogenesis and other metabolic fuels must be functional.
There must be an adequate supply of endogenous fat, glycogen and gluconeogenic substrates (amino acids,glycerol, lactate).
![Page 5: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/5.jpg)
Glucose Metabolism After Birth
Cessation of maternal glucose supply
Surge in glucagon, catecholamineDecrease insulin
Gluconeogenesis: Hepatic glycogen, amino acid, fatty acid metabolism
Normal blood glucose
![Page 6: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/6.jpg)
DEFINITION The definition of clinically significant hypoglycemia remains controversial.
Usually defined as blood glucose levels of <40 mg/dl (plasma glucose <45 mg/dl ).
Clinical Definition Must fulfill Whipple’s Triad
a) Low glucose
b) S&S consistent with hypoglycemia
(eg. Jitteriness, tremors, lethargy, seizures, apnea, cyanotic spells, hypotonia, difficulty feeding, hypothermia, coma)
c) Resolution of S&S after restoring glucose
![Page 7: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/7.jpg)
Cornblath’s “operational threshold” 2000AD
Healthy full term infant
a) < 24 hr of age – 30 to 35 may acceptable at one time, but should not be < 45 after feeding or after 24 hrs.
b) > 24 hr threshold is 45 to 50 mg/dl
Infants with abnormal signs or symptoms- 45 mg/dl.
Asymptomatic Infants with risk factors- 36mg/dl.
For any baby if glucose is < 20 to 25 I.V glucose is needed.
![Page 8: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/8.jpg)
Knowledge gaps
The complex nature and maturational features of global and regional brain energy use remains to be studied in human neonates.
There is no evidence based study to identify any specific plasma glucose concentration to define pathologic hypoglycemia.
There is great inconsistency in the sources and sampling methods of blood and the methods used for subsequent analysis.
There are no noninvasive methods for measuring glucose intermittently or continuously.
The role of EEG and Neuroimaging in the management or prediction of hypoglycemia related neuronal injuries remains to be determined.
![Page 9: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/9.jpg)
DEFINITION
PERSISTENT HYPOGLYCEMIA-
Require infusions of large amounts of glucose (>12 mg/kg/min) to maintain normoglycemia.
Persisting or recurring beyond the first 5 - 7 days of life.
** Prompt recognition is essential!!
These conditions are associated with severe disease at substantial risk of developing severe mental retardation and epilepsy.
![Page 10: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/10.jpg)
INCIDENCE
Overall Incidence = 1- 5/1000 live births
Normal newborns – 10% if feeding is delayed for 3-6 hours after birth
At-Risk Infants –
LGA – 16%
Preterm – 15%
SGA – 15%
IDM – 20%
![Page 11: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/11.jpg)
ETIOLOGY
1. Endocrine disorders
2. Decreased substrate
3. Increased utilization
4. Mixed
![Page 12: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/12.jpg)
ETIOLOGY - I
1. Endocrine disordersi. Hyperinsulinemia-
Major cause of persistent hypoglycemia
May cause increased brain injury
Decreased glucose levels
Prevent brain from utilizing non glucose substrates by blocking FA release and ketone body synthesis.
![Page 13: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/13.jpg)
A. Infant of diabetic mother – most common
B. Congenital hyperinsulinism (P)
C. Beckwith-weidmann syndrome (P)
D. Erythroblastosis fetalis
E. Exchange transfusion
F. Insulin producing tumor (P)
G. Maternal beta agonist, tocolytics *P= Persistent
H. Improperly placed umbilical artery catheter
I. Inadvertent insulin administration
![Page 14: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/14.jpg)
ii. Other endocrine disorders – def of antagonist hormones
A. Immaturity of hepatic enzymes for glucose production
B. Hypopituitarism (P)
C. Hypothalamic deficiency
D. Hypothyroidism (P)
E. Adrenal insufficiency (P)
F. Glucagon or epinephrine deficiency
![Page 15: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/15.jpg)
ETIOLOGY - II
2. Decreased substrate availability
A. Intrauterine growth restriction
B. Prematurity
C. Reduced Glycogen stores
D. Reduced fat stores
E. Glycogen storage disease (P)
F. Inborn errors (eg. Fructose intolerance, defects in amino acid metabolism, mitochondrial fatty acid oxidation & ketogenesis defects ) (P)
![Page 16: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/16.jpg)
ETIOLOGY III
3. Increased utilization
A. Increased brain wt to body wt and liver wt ratio (P)
B. Perinatal asphyxia
C. Hypothermia
D. Polycythemia
![Page 17: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/17.jpg)
ETIOLOGY IV
4. Miscellaneous/multiple mechanisms
A. Sepsis
B. Congenital heart disease
C. Central nervous system abnormalities (P)
![Page 18: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/18.jpg)
ETIOLOGY - DISCUSSION
Prematurity and IUGR
Hepatic glycogen stores are limited in both preterm infants and SGA infants.
Increased brain-to-bodyweight ratio in IUGR babies.
Studies in preterm and IUGR infants have found altered patterns of insulin secretion, substrate metabolism, and hormonal responses to changes in blood glucose concentration compared with AGA term infants.
Asphyxia and hypothermia - increased metabolism of glucose with rapid depletion of glycogen stores – hypoglycemia.
![Page 19: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/19.jpg)
ETIOLOGY - DISCUSSION
Infants of diabetic mothers (IDMS)
Placental glucose transport is increased, leading to fetal hyperglycemia, which stimulates secretion of insulin by the fetal pancreas.
Also have exaggerated pancreatic insulin secretion in response to a given glucose load compared with non IDMs.
Insulin inhibits gluconeogenesis and increases glucose utilization in insulin sensitive tissues.
After delivery, increased blood glucose concentrations no longer are present, but the hyperinsulinemia persists for 24 to 72 hrs.
![Page 20: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/20.jpg)
ETIOLOGY - DISCUSSION
Erythroblastosis fetalis and beta-agonist tocolytic agents
Infants with erythroblastosis fetalis have increased levels of insulin and an increase in the number of pancreatic beta cells. Mechanism unclear.
Exchange transfusion - infant receives a significant glucose load, with subsequent exaggerated insulin response from pancreas.
Use of beta-agonist tocolytic agents such as terbutaline - is associated with hyperinsulinemia in the newborn, esp if used for more than 2 weeks and discontinued less than 1 week prior to delivery.
![Page 21: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/21.jpg)
ETIOLOGY - DISCUSSION Hyperinsulinism
Some perinatal asphyxia or IUGR infants demonstrate hyperinsulinemia that may rarely persist for as long as 4 weeks.
Congenital hyperinsulinism - most common cause of hypoglycemia persisting beyond the first week of life. Autosomal recessive form - linked to a defect in the sulfonylurea receptor or K+ -ATP
channel.
Autosomal dominant form of hyperinsulinemia also occurs but mutation not identified.
Beckwith-Weidemann syndrome - associated with hyperplasia of multiple organs, including the pancreas, with consequent increased insulin secretion.
localized islet cell adenomas can also cause hyperinsulinism.
![Page 22: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/22.jpg)
ETIOLOGY - DISCUSSION
Inborn errors of metabolism
May affect either the availability of gluconeogenic precursors or the function of the enzymes required for production of hepatic glucose.
Glycogen storage disease, galactosemia, fatty acid oxidation defects, carnitine deficiency, several of the amino acidemias, hereditary fructose intolerance (fructose-1,6-diphos-phatase deficiency), and defects of other gluconeogenic enzymes.
Endocrine disorders such as hypopituitarism and adrenal failure also can result in hypoglycaemia.
![Page 23: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/23.jpg)
SYMPTOMS
I. Tremors, Jitteriness or Irritability
II. Seizures, Coma
III. Lethargy, Apathy and Limpness
IV. Poor feeding, Vomiting
V. Apnea
VI. Weak or High pitched cry
VII.Cyanosis
VIII.Many infants have no symptoms
![Page 24: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/24.jpg)
SCREEENING Done in infants at risk and those with symptoms.
Maternal risk factors
Maternal diabetes mellitus– risk correlates with quality of control more than category of diabetes
Intrapartum administration of Glucose Maternal drug therapy including: β-blockers,Oral hypoglycaemic
agents, Valproate Family history of metabolic disorders (e.g. Medium-chain acyl-CoA
dehydrogenase deficiency (MCADD))
![Page 25: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/25.jpg)
SCREENING
New born Risk factors
Prematurity less than 37 weeks
Small for gestational age (SGA) (less than 10thpercentile) or intrauterine growth restriction
Low birth weight (less than 2500 gram)
Large for gestational age (LGA) (greater than 90th percentile)
![Page 26: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/26.jpg)
Other New Born Risk factors
Macrosomia
Perinatal hypoxic-ischaemic insult
Respiratory distress
Sepsis or suspected infection
Hypothermia
Polycythaemia
Congenital cardiac abnormalities
Endocrine disorders
Family history of metabolic disorders
Inborn errors of metabolism
Rhesus haemolytic disease
Erythroblastosis fetalis
Obvious syndromes:
§ Beckwith-Wiedemann syndrome
§ Midline defects (e.g. cleft palate)
Inadequate feeding
Weaning of IV fluids
![Page 27: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/27.jpg)
HOW TO SCREEN?
![Page 28: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/28.jpg)
SRCREENING TOOLS
Prior to blood sampling:
Ensure the baby receives appropriate pain reducing strategies
The use of oral sucrose is not contraindicated.
To avoid any effect on the newborn’s blood sugar, oral sucrose should preferably be given only a short duration (e.g. less than 30 seconds) before the blood sampling.
![Page 29: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/29.jpg)
SCREENING TOOLSA Blood glucose level (BGL) may be measured using a:
Formal measurement:
o Blood gas machine/analyser – use a capillary tube or blood gas syringe
o Biochemical laboratory – use, in order of preference, either a fluoride oxalate (grey top), clotted (red top), or heparin (green top) tube.
Bedside glucometer:
o Considered a screening tool
o Use a glucometer that uses a glucose oxidase test strip with electrochemical sensor
o Although newer generation glucometers have improved accuracy glucometers are less accurate than formal measurements in lower BGL ranges
![Page 30: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/30.jpg)
SCREENING TOOLS Factors affecting BGL results
The sample collection technique:
o Squeezing a poorly perfused heel may cause haemolysis resulting in a falsely low BGL reading
o Inadequate clearing of the umbilical catheters before sampling
o Never take BGL from a venous or arterial line where Glucose is infusing
o A delay between collection and laboratory analysis may produce a falsely low BGL reading
Results from arterial, venous and capillary samples may vary by 10-15%
High haematocrit may contribute to low BGL readings in bedside glucometers or when there is a delay in processing samples.
![Page 31: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/31.jpg)
MANAGEMENT
Why should hypoglycemia in the newborn be managed aggressively ?
I. Glucose is the predominant fuel for the newborn brain.
II. Hypoglycemia predisposes to long term neurological damage.
III. Common sequelae of hypoglycemia are disturbances of neurologic development and intellectual function.
IV. Minor deficits - spasticity and ataxia and seizure disorders can also occur.
V. The occurrence of these may be related to etiology of hypoglycaemia.
![Page 32: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/32.jpg)
MANAGEMENT : PREVENTION
Discuss preventative care with the parents/carers.
Keep the baby warm
• At birth dry and remove wet linen
• Initiate early skin to skin contact (SSC) (baby’s gestation and condition permitting)
o Encourage ongoing SSC to assist thermoregulation and promote frequent breastfeeds
o If required, use warmed blankets, overhead heaters, incubators and heated mattresses ETC.
![Page 33: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/33.jpg)
MANAGEMENT : PREVENTION Provide energy by: Initiating early feeds within 30-60 minutes of birth with:
o Breastfeeding
o Assist feeds (Paladai or NG feeds) if baby is less than 35 weeks gestation
o If baby is not feeding well, give colostrum (expressed)
For at risk babies – continue oral feeding at least three hourly or more frequently.
Separation of mother and baby should be avoided.
Breastfeeding may enhance ketogenesis which is alternate fuel for brain.
If enteral feeding is not possible or contraindicated – commence IV therapy.
![Page 34: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/34.jpg)
Feeding? IV therapy? Medication?
MANAGEMENT : TREATMENT
![Page 35: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/35.jpg)
TREATMENT– Oral Feeds
Can be used in asymptomatic infants
Only breast milk or formula (never administer glucose water!!)
Follow up blood glucose within 1 hour of feeding.
If the glucose level doesn’t rise, a more aggressive therapy may be needed.
![Page 36: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/36.jpg)
Asymptomatic hypoglycemia –
![Page 37: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/37.jpg)
TREATMENT
Management of Symptomatic hypoglycemia-
Bolus of 2 mL/kg of 10% dextrose
Symptomatic hypoglycemia
Start Glucose infusion @ 6-8mg/kg/min
Check Blood sugar at 30-60min
BS >50, give for 24 hrs start tapering once 2
reading above 50
BS <50,increase GIR in steps of 1-2 upto
12
![Page 38: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/38.jpg)
TREATMENT
Calculation of Glucose Infusion Rate (GIR) GIR = Rate of IV fluids (in ml/kg/day) x % of dextrose infused mg/kg/min
144
GIR in infants on IV fluids + Oral feeds
Glucose infusion rate while on feeding (mg/kg/min) =
[IV rate (ml/hr) x Dextrose conc (g/dl) x .0167 / wt (kg)] + [Feed rate(ml/hr) x Dextrose conc* (g/dl) x
.0167 / wt (kg)]
Amount of dextrose in milk : Breast milk = 7.1 gm/dL ,Term formula = 7.1gm/dL, Preterm formula = 8.5 gm/dL .
![Page 39: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/39.jpg)
GIR can also be calculated as:
GIR = Total glucose given (IV + Oral ) per 24 hr mg/kg/min
Wt x 1.44
![Page 40: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/40.jpg)
SEVERE,PERSISTENT OR RECURRENT HYPOGLYCEMIA Symptomatic including seizures or altered level of consciousness
Severe:
o BGL less than 20 mg/dl or unexpectedly low for the clinical situation
o Baby requiring GIR >10 at any time
Persistent or recurrent
Early onset hypoglycaemia that is persisting/recurring after 72 hours
Associated with other abnormalities such as
o Midline defects o Micropenis
o Exomphalos o Erratic temperature control
Unusual in presentation and/or no maternal or neonatal risk factors present
Family history of Sudden Infant Death Syndrome, MCADD deficiency, Reye’s syndrome or developmental delay
![Page 41: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/41.jpg)
EVALUATION FOR PERSISTENT HYPOGLYCEMIA
First line investigations - ( For Hyperinsulinemic hypoglycemia )
Draw a blood sample when blood glucose is <40 and test for-
Glucose
Insulin
Cortisol
Beta hydroxybutyrate and FFA levels- if decreased can indicate excessive insulin action.
![Page 42: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/42.jpg)
EVALUATION CONT… If insulin level is normal for the blood glucose level,
consider additional testing-
I. Growth hormone
II. ACTH
III. Thyroxine (T4) and TSH
IV. Glucagon
V. Plasma amino acids
![Page 43: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/43.jpg)
VI. Urine ketones
VII. Urine reducing substance
VIII. Urine amino acids
IX. Urine organic acids
X. Genetic testing for mutations like SUR1 & Kir6.2
![Page 44: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/44.jpg)
OTHER CAUSES TO BE RULED OUT--
If symptoms persist after the glucose concentration is within normal range other etiologies should be considered-
I. Sepsis
II. CNS disease
III. Toxic exposure
IV. Metabolic abnormalities
a. Hypocalcemia
b. Hyponatremia or Hypernatremia
c. Hypomagnesemia
d. Pyridoxine deficiency
![Page 45: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/45.jpg)
V. Adrenal insufficiency
VI. Heart failure
VII. Renal failure
VIII. Liver failure
![Page 46: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/46.jpg)
PHARMACOLOGICAL INTERVENTION
If the Glucose infusion rate is greater than 10-12 mg/kg/minute:
o Consider pharmacological intervention for severe, persistent or recurrent hypoglycaemia
o Refer for specialist management (e.g. paediatric endocrinologist/metabolic physician) where required as this is almost certainly hyperinsulinaemia
Ensure diagnostic samples have been collected prior to using specific medication
![Page 47: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/47.jpg)
GLUCAGON
Dose – 0.025 – 0.2 mg/kg, maximum 1 mg i.m , sub cutaneous or i.v .
Indication – It may be given to infants with good glycogen stores, but effects is temporary.
May not work if
Reduced glycogen stores
Glycogen storage disease
![Page 48: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/48.jpg)
Hydrocortisone
Dose: 10 mg/kg/day IV q 12 hrs
Add after 24-48 hours of IV therapy but only for temporary treatment for 1-2 days then slowly reduce dose.
![Page 49: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/49.jpg)
Diazoxide
Dose: 5 - 8 mg/kg/day PO q 8 hrs.
Indication: Infants who have persistent hyperinsulinemia (e.g.. Nesidioblastosis)
Monitor: BP – sodium and fluid retention is a common side-effect.
![Page 50: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/50.jpg)
OCTREOTIDE
Dose – 5-20 mcg/kg/day subcutaneously or intravenously q 6 – 8 hrly.
Indication – In hyperinsulinemic patients when Diazoxide does not successfully control glucose level.
Avoid abrupt withdrawal
Has been associated with necrotising enterocolitis
![Page 51: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/51.jpg)
SURGERY
Pancreatectomy – Decreases insulin secretion.
![Page 52: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/52.jpg)
CONCLUSION
Awareness of risk factors that predispose infants to hypoglycemia allows for screening of those at risk.
If detected hypoglycemia can be treated promptly, thereby preventing the development of severe or symptomatic hypoglycemia, which is associated with adverse outcome.
Asymptomatic hypoglycaemia: It is likely that hypoglycemia contributes to abnormal neurodevelopmental outcome in infants with other risk factors for brain injury, such as prematurity or HIE .
![Page 53: Yusuf Transient & persistent hypoglycemia in neonates](https://reader034.vdocument.in/reader034/viewer/2022052523/55648024d8b42a361d8b49a7/html5/thumbnails/53.jpg)
Thank You
GGlucose molecule